Der ungewöhnliche Fall: Ein Corpus Alienum im Urachus

Hatzinger, Martin; Stastny, M.; Wirsam, K.; Sohn, Michael

doi:10.1055/s-0030-1247417

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to malignant urachal tumors, several other intermediate and benign tumors or conditions of the urachus have been reported some mimicking urachal cancer and thus posing a differential diagnostic problem. Tumors or conditions rated as intermediate include inflammatory myofibroblastic tumors (IMT) [ 297 – 300 ], a solitary fibrous tumor (SFT) [ 301 ], desmoid fibromatoses [ 302 , 303 ], a hemangiopericytoma [ 304 ], and a Castleman's disease [ 305 ], while benign tumors and conditions include dermoid cysts [ 301 , 306 ], teratomas [ 307 , 308 ], leiomyomas [ 309 , 310 ], (fibrous) hamartomas [ 311 , 312 ], a hemangioma [ 313 ], a fibroadenoma [ 314 ], malakoplakia [ 315 ], abscesses [ 316 – 318 ], a xanthogranulomatous urachitis [ 319 ], a urachal tuberculosis [ 320 ], actinomycosis [ 321 – 323 ], an endometriosis [ 324 ], a perforated colonic diverticulitis [ 325 ], and even a fishbone within an urachal cyst [ 326 ].…”

Section: Specific Review Data: Nonadenocarcinoma Neoplasmsmentioning

confidence: 99%

Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data

et al. 2018

View full text Add to dashboard Cite

Urachal cancer (UrC) is a rare but aggressive cancer. Due to overlapping histomorphology, discrimination of urachal from primary bladder adenocarcinomas (PBAC) and adenocarcinomas secondarily involving the bladder (particularly colorectal adenocarcinomas, CRC) can be challenging. Therefore, we aimed to give an overview of helpful (immunohistochemical) biomarkers and clinicopathological factors in addition to survival analyses and included institutional data from 12 urachal adenocarcinomas. A PubMed search yielded 319 suitable studies since 1930 in the English literature with 1984 cases of UrC including 1834 adenocarcinomas (92%) and 150 nonadenocarcinomas (8%). UrC was more common in men (63%), showed a median age at diagnosis of 50.8 years and a median tumor size of 6.0 cm. No associations were noted for overall survival and progression-free survival (PFS) and clinicopathological factors beside a favorable PFS in male patients (p = 0.047). The immunohistochemical markers found to be potentially helpful in the differential diagnostic situation are AMACR and CK34βE12 (UrC versus CRC and PBAC), CK7, β-Catenin and CD15 (UrC and PBAC versus CRC), and CEA and GATA3 (UrC and CRC versus PBAC). Serum markers like CEA, CA19-9 and CA125 might additionally be useful in the follow-up and monitoring of UrC.

show abstract